Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer

Phase 2

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Endostar
Drug: Oxaliplatin
Drug: Folinic acid
Drug: 5-FU

First Posted Date: 2013-04-16

Last Posted Date: 2013-04-16

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT01832948

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer

Early Phase 1

Completed

Conditions: Acinar Cell Adenocarcinoma of the Pancreas
Duct Cell Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer

Interventions: Drug: oxaliplatin
Drug: irinotecan
Drug: leucovorin
Drug: 5-fluorouracil
Drug: capecitabine
Radiation: radiation
Procedure: surgery
Drug: gemcitabine

First Posted Date: 2013-04-01

Last Posted Date: 2018-09-04

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 23

Registration Number: NCT01821612

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

and more 11 locations

Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab

Phase 2

Conditions: Mucinous Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Mucinous Adenocarcinoma of the Colon
Signet Ring Adenocarcinoma of the Colon
Signet Ring Adenocarcinoma of the Rectum
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions: Biological: panitumumab
Drug: irinotecan hydrochloride
Drug: fluorouracil
Drug: leucovorin calcium

First Posted Date: 2013-03-20

Last Posted Date: 2019-03-27

Lead Sponsor: John Hays

Target Recruit Count: 16

Registration Number: NCT01814501

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Pancreatic Cancer
Esophagogastric Cancer
Non-small Cell Lung Cancer
Breast Cancer
Colorectal Cancer

Interventions: Drug: Andecaliximab
Drug: Gemcitabine
Drug: Carboplatin
Drug: Leucovorin
Drug: Nab-paclitaxel
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Oxaliplatin
Drug: 5-FU
Drug: Bevacizumab
Drug: Irinotecan

First Posted Date: 2013-03-04

Last Posted Date: 2020-06-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 236

Registration Number: NCT01803282

Locations: 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸
University of Southern California (USC), Los Angeles, California, United States
🇺🇸
Parkview Research Center, Fort Wayne, Indiana, United States

and more 15 locations

Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases

Phase 2

Conditions: Colorectal Cancer

Interventions: Drug: Cetuximab
Drug: Bevacizumab
Drug: Irinotecan
Drug: 5-FU
Drug: Oxaliplatin
Drug: Folinic Acid

First Posted Date: 2013-03-01

Last Posted Date: 2019-09-11

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 91

Registration Number: NCT01802645

Locations: 🇩🇪
Klinikum Coburg GmbH, Coburg, Germany
🇩🇪
Klinikum Landshut gGmbH, Landshut, Germany
🇩🇪
Rems-Murr-Klinikum Winnenden, Winnenden, Germany

and more 12 locations

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Phase 2

Terminated

Conditions: Breast Neoplasms

Interventions: Drug: Doxorubicin
Biological: Trastuzumab
Drug: Cyclophosphamide
Drug: Paclitaxel
Drug: Epirubicin
Drug: Docetaxel
Drug: Fluorouracil
Drug: Carboplatin

First Posted Date: 2013-01-29

Last Posted Date: 2022-11-01

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 7

Registration Number: NCT01779050

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Sorafenib + mFOLFOX for Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Hepatocellular Cancer

Interventions: Drug: Leucovorin
Drug: Fluorouracil
Drug: Oxaliplatin
Drug: Sorafenib

First Posted Date: 2013-01-25

Last Posted Date: 2020-04-22

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 40

Registration Number: NCT01775501

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Capecitabine
Drug: Cisplatin
Drug: Placebo
Drug: Pertuzumab
Drug: Trastuzumab

First Posted Date: 2013-01-24

Last Posted Date: 2020-12-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 780

Registration Number: NCT01774786

Locations: 🇺🇸
Florida Cancer Specialists - SCRI; Pharmacy, Fort Myers, Florida, United States
🇺🇸
Weill Medical College of Cornell University; Division of Hematology & Medical Oncology, New York, New York, United States
🇺🇸
University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States

and more 169 locations

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

Phase 2

Terminated

Conditions: HER2 Positive Esophagogastric Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Oxaliplatin
Drug: Lapatinib
Radiation: Radiation Therapy

First Posted Date: 2013-01-16

Last Posted Date: 2016-06-13

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 12

Registration Number: NCT01769508

Locations: 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists-North, St. Petersburg, Florida, United States
🇺🇸
Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States

and more 6 locations

Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Neoplasms

Interventions: Drug: 5-fluorouracil
Drug: bevacizumab
Drug: capecitabine
Drug: irinotecan
Drug: folinic acid
Drug: oxaliplatin

First Posted Date: 2013-01-10

Last Posted Date: 2017-09-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 280

Registration Number: NCT01765582

Locations: 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸
Johns Hopkins Univ; Bunting Blaustein Cancer Center, Baltimore, Maryland, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

and more 42 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy